LEADER 00801nam0-2200301---450- 001 990005660590403321 005 20101213125639.0 035 $a000566059 035 $aFED01000566059 035 $a(Aleph)000566059FED01 035 $a000566059 100 $a19990604d1916----km-y0itay50------ba 101 0 $aita 102 $aIT 105 $ay-------001yy 200 1 $a<>dinamismo$fGiacomo Donati 210 $aForlė$cCasa Editrice Tipografica ditta Luigi Bordandini$d1916 215 $a46 p.$d21 cm 610 0 $aDinamismo 676 $a121 700 1$aDonati,$bGiacomo$0217762 801 0$aIT$bUNINA$gREICAT$2UNIMARC 901 $aBK 912 $a990005660590403321 952 $aP.1 FG 2087$bIST.ST.FIL. 5322$fFLFBC 959 $aFLFBC 996 $aDinamismo$9600666 997 $aUNINA LEADER 01708nam 2200421 a 450 001 9910695785803321 005 20070320112430.0 035 $a(CKB)5470000002371919 035 $a(OCoLC)86076826 035 $a(EXLCZ)995470000002371919 100 $a20070320d2006 ua 0 101 0 $aeng 135 $aurmn|---||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aEnd-stage renal disease$b[electronic resource] $eMedicare payments for all ESRD services, including injectable drugs, should be bundled : testimony before the Committee on Ways and Means, House of Representatives /$fstatement of David M. Walker 210 1$a[Washington, D.C.] :$cU.S. Government Accountability Office,$d[2006] 215 $a5 pages $cdigital, PDF file 225 1 $aTestimony ;$vGAO-07-266 T 300 $aTitle from title screen (viewed on Mar. 13, 2007). 300 $a"For release ... December 6, 2006." 300 $aPaper version available from: U.S. Government Accountability Office, 441 G St., NW, Rm. LM, Washington, D.C. 20548. 320 $aIncludes bibliographical references. 517 $aEnd-stage renal disease 606 $aMedicare$xEconomic aspects 606 $aChronic renal failure 615 0$aMedicare$xEconomic aspects. 615 0$aChronic renal failure. 700 $aWalker$b David M$g(David Michael),$f1951-$01380682 712 02$aUnited States.$bCongress.$bHouse.$bCommittee on Ways and Means. 712 02$aUnited States.$bGovernment Accountability Office. 801 0$bGPO 801 1$bGPO 906 $aBOOK 912 $a9910695785803321 996 $aEnd-stage renal disease$93449621 997 $aUNINA